Tiago Fauth
Stock Analyst at Wells Fargo
(2.97)
# 2,394
Out of 5,182 analysts
145
Total ratings
42.2%
Success rate
0.55%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $135.98 | +59.58% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $6.94 | +159.37% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $566.99 | -26.98% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $2.63 | +280.23% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $69.22 | +5.46% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $37.34 | -16.98% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $308.51 | +28.03% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $23.99 | +170.95% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $74.52 | +1.99% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $5.16 | +35.66% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $28.75 | +251.30% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.21 | +147.93% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $11.01 | +136.15% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.49 | +17.32% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $68.85 | +8.93% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $226.66 | -60.73% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $13.50 | +277.78% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $53.81 | +123.03% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $28.62 | -86.02% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $4.85 | +188.66% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $57.18 | +424.66% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $9.07 | +186.66% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $4.16 | +573.08% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $40.95 | +97.80% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $400 | $4.51 | +8,769.18% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.76 | +695.45% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.59 | +2,038.36% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $44.65 | -35.05% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.44 | +802.78% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.89 | +349.83% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.61 | +24.22% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $783.74 | -56.62% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $340.18 | -23.86% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $135.98
Upside: +59.58%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $6.94
Upside: +159.37%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $566.99
Upside: -26.98%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.63
Upside: +280.23%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $69.22
Upside: +5.46%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $37.34
Upside: -16.98%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $308.51
Upside: +28.03%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $23.99
Upside: +170.95%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $74.52
Upside: +1.99%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.16
Upside: +35.66%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $28.75
Upside: +251.30%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.21
Upside: +147.93%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $11.01
Upside: +136.15%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.49
Upside: +17.32%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $68.85
Upside: +8.93%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $226.66
Upside: -60.73%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $13.50
Upside: +277.78%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $53.81
Upside: +123.03%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $28.62
Upside: -86.02%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.85
Upside: +188.66%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $57.18
Upside: +424.66%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $9.07
Upside: +186.66%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $4.16
Upside: +573.08%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $40.95
Upside: +97.80%
Mar 24, 2023
Reiterates: Neutral
Price Target: $400
Current: $4.51
Upside: +8,769.18%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.76
Upside: +695.45%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.59
Upside: +2,038.36%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $44.65
Upside: -35.05%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.44
Upside: +802.78%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.89
Upside: +349.83%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.61
Upside: +24.22%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $783.74
Upside: -56.62%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $340.18
Upside: -23.86%